Cognition Therapeutics Inc

Research Cognition Therapeutics Inc (CGTX) on Bullrun: market cap USD 97.91M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 97.91M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 0-USD 23.49M-USD 24.59Mn/a-0.32USD 36.81MUSD 638.00KUSD 34.27M
FY2024USD 0-USD 33.97M-USD 28.48Mn/a-0.86USD 25.01MUSD 814.00KUSD 18.75M
FY2023n/a-USD 25.79M-USD 16.17Mn/a-0.86USD 29.92MUSD 1.24MUSD 24.47M
FY2022n/a-USD 21.40M-USD 18.70Mn/a-0.91USD 41.56MUSD 967.00KUSD 40.25M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 97.91Mn/an/an/a
20252025-12-31USD 120.02Mn/an/an/a
20242024-12-31USD 41.90Mn/an/an/a
20232023-12-29USD 59.43Mn/an/an/a
20222022-12-30USD 60.88Mn/an/an/a
20212021-12-31USD 140.49Mn/an/an/a

About Cognition Therapeutics Inc

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Cognition Therapeutics Inc's market cap?

Cognition Therapeutics Inc's market capitalization is USD 97.91M.

What does Cognition Therapeutics Inc do?

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.